410 related articles for article (PubMed ID: 28691309)
1. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
2. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
Asero R; Marzano AV; Ferrucci S; Cugno M
Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
[TBL] [Abstract][Full Text] [Related]
3. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
[No Abstract] [Full Text] [Related]
4. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
[TBL] [Abstract][Full Text] [Related]
6. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
7. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
9. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU.
Asero R; Marzano AV; Ferrucci S; Cugno M
J Allergy Clin Immunol Pract; 2017; 5(6):1740-1742. PubMed ID: 28866106
[No Abstract] [Full Text] [Related]
10. D-dimer levels decline after immunosuppressive treatment rather than anticoagulant treatment in severe autoimmune chronic spontaneous urticaria.
Baskurt D; Sarac E; Asero R; Kocatürk E
Eur Ann Allergy Clin Immunol; 2024 Jan; 56(1):42-44. PubMed ID: 36305339
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
13. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
[TBL] [Abstract][Full Text] [Related]
14. Long-term management of chronic spontaneous urticaria with omalizumab.
Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
[TBL] [Abstract][Full Text] [Related]
15. D-dimer: a biomarker for antihistamine-resistant chronic urticaria.
Asero R
J Allergy Clin Immunol; 2013 Oct; 132(4):983-6. PubMed ID: 23763979
[No Abstract] [Full Text] [Related]
16. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
[No Abstract] [Full Text] [Related]
17. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
[No Abstract] [Full Text] [Related]
18. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
[No Abstract] [Full Text] [Related]
19. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
20. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]